Meta-analysis of transcatheter arterial chemoembolization plus radiofrequency ablation versus transcatheter arterial chemoembolization alone for hepatocellular carcinoma

作者：Dejun Yang, Kunlun Luo, Hong Liu, Bing Cai, Guo‐Qing Tao, Xiao-Fang Su, Xiaojuan Hou, Fei Ye, Xiangyong Li, Zhiqiang Tian · 发表于：Oncotarget · 年份：2016 · DOI：10.18632/oncotarget.13813 · 被引用次数：56 · 研究领域：Hepatocellular Carcinoma Treatment and Prognosis、Liver Disease Diagnosis and Treatment、Liver Disease and Transplantation

// De-jun Yang 1, * , Kun-lun Luo 3, * , Hong Liu 3, * , Bing Cai 2 , Guo-qing Tao 2 , Xiao-fang Su 3 , Xiao-juan Hou 4 , Fei Ye 4 , Xiang-yong Li 3 , Zhi-qiang Tian 2, 3, 4 1 Department of Gastrointestinal Surgery, The Changzheng Hospital, Second Military Medical University, Shanghai, 200003, China 2 Department of General Surgery, Wuxi People's Hospital Affiliated Nanjing Medical University, Wuxi 214023, China 3 Department of General Surgery and Rehabilitation Medicine and Oncology, The 101st Hospital of Chinese PLA, Wuxi 214044, China 4 Tumor Immunology and Gene Therapy Center, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai 200438, China * These authors contributed equally to this work Correspondence to: Zhi-qiang Tian, email: zhiqiangtiann@163.com Xiang-yong Li, email: xiangyongl@126.com Keywords: transcatheter arterial chemoembolization, radiofrequency ablation, hepatocellular carcinoma, meta-analysis Received: June 11, 2016      Accepted: November 30, 2016      Published: December 07, 2016 ABSTRACT This meta-analysis was conducted to compare transcatheter arterial chemoembolization (TACE) plus radiofrequency ablation (RFA) with TACE alone for hepatocellular carcinoma. We searched MEDLINE, EMBASE and CENTRAL for all relative randomized controlled trials (RCTs) and retrospective studies until October 31 2016. Tumor response, recurrence-free survival, overall survival and postoperati...